Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial

Amer M. Zeidana Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USACorrespondence[email protected]
View further author information

Cynthia Z. Qib Analysis Group, Inc., Boston, MA, USAView further author information

Hongbo Yangb Analysis Group, Inc., Boston, MA, USAView further author information

Andy Garnhamc Astellas Pharma, Inc., Northbrook, IL, USAView further author information

Manasee V. Shahc Astellas Pharma, Inc., Northbrook, IL, USAView further author information

Bhavik J. Pandyac Astellas Pharma, Inc., Northbrook, IL, USAView further author information

Click to increase image sizeClick to decrease image size

Acknowledgments

Medical writing assistance was provided by Shelley Batts, PhD, an employee of Analysis Group, Inc. and funded by the study sponsor.

Disclosure statement

Bhavik J. Pandya, Andy Garnham, and Manasee V. Shah are employees of Astellas and hold stock/options. Cynthia Z. Qi and Hongbo Yang are employees of Analysis Group, Inc., which has received consulting fees from Astellas for this study. Amer M. Zeidan is a consultant for Astellas and has received honoraria and research funding.

Additional information

Funding

This study was funded by Astellas Pharma, Inc.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial

Information for

Open access

Opportunities

Help and information

Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial

Acknowledgments

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature